mesalamine FDA label update (2026-07-27)

2 min read Aug 18, 2026, 7:11 AM

Medications Regulatory Update Ulcerative colitis Inflammatory bowel disease

Why This Matters

Updated FDA prescribing information affects safety monitoring and counseling for people with ulcerative colitis who take mesalamine, including children meeting the weight threshold. The label highlights kidney monitoring and rare but serious hypersensitivity and skin reactions that could require stopping the drug.

Who Should Pay Attention

Adults and pediatric patients (≥24 kg) with ulcerative colitis taking or considering mesalamine; prescribing clinicians and pharmacists involved in IBD care.

Study Snapshot

Story typeRegulatory

Evidence typeRegulatory update

Study statusHuman prescription drug

Source depthRegulatory record

What To Know

This DailyMed entry is an FDA drug-label update for mesalamine delayed‑release tablets (an aminosalicylate) used to treat mild‑to‑moderate ulcerative colitis in adults and children ≥24 kg.

The label emphasizes recommended baseline and periodic renal monitoring, warns about a mesalamine‑induced acute intolerance syndrome that can mimic a UC flare, and lists hypersensitivity reactions (including myocarditis/pericarditis), hepatic failure risk in patients with pre‑existing liver disease, severe cutaneous adverse reactions, photosensitivity, and nephrolithiasis among precautions.

If you are taking mesalamine, note the label advises assessing renal function before and during therapy and discontinuing the drug if renal function worsens. It also advises stopping mesalamine if signs of severe hypersensitivity, acute intolerance, or severe skin reactions appear.

The label includes other practical cautions such as avoiding use in patients with upper GI obstruction and advising sun protection for those with pre‑existing skin conditions. This summary is grounded in the FDA/DailyMed label text; it does not substitute for reading the full prescribing information or for medical advice from your clinician.

For personal questions about risks (for example, kidney disease, liver disease, pregnancy, or drug interactions), consult your prescriber or pharmacist.

Keep In Mind

This is a regulatory drug‑label (DailyMed/NLM reflecting FDA‑approved prescribing information). It summarizes indications, warnings, and monitoring requirements but is not new clinical trial data. Individual management decisions should come from a clinician.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source

Regulatory update Evidence type derived from source or registry metadata.

PublicationopenFDA

PublisherU.S. Food and Drug Administration

SponsorMajor Pharmaceuticals

Study typeDrug Label Update

Indexed viaopenFDA

Source typeRegulatory record

PublishedJul 27, 2026, 12:00 AM

Content availableRegulatory record

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.